You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
23 Items
Cancer Type: Genitourinary, Renal cell / Kidney     
Drugs Used:
aXitinib (Unfunded),
pembrolizumab (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
New
Dec 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer
... Show more tags
Drugs Used:
pembrolizumab (Unfunded),
pemetrexed,
CISplatin
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Drugs Used:
pembrolizumab (Unfunded),
PACLitaxel,
CARBOplatin
... Show more tags
Quick Link(s):
Regimen Monograph
Aug 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer
... Show more tags
Drugs Used:
pembrolizumab (Unfunded),
pemetrexed,
CARBOplatin
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
... Show more tags
Drugs Used:
daSATinib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
... Show more tags
Drugs Used:
daSATinib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Irinotecan - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for First Line Metastatic Colorectal Small Bowel or Appendiceal Cancer
... Show more tags
Drugs Used:
PANitumumab,
irinotecan,
leucovorin,
fluorouracil
... Show more tags
Quick Link(s):
Regimen Monograph
Aug 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
Exceptional Access Program
    gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
... Show more tags
Drugs Used:
gefitinib
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Head and Neck     
Intent: Palliative
Drugs Used:
gefitinib (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Aug 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
New Drug Funding Program
    Ipilimumab - Previously Untreated Advanced Unresectable Melanoma
New Drug Funding Program
    Ipilimumab - Previously Treated Advanced Unresectable Melanoma
... Show more tags
Drugs Used:
ipilimumab
... Show more tags
Quick Link(s):
Regimen Monograph
Updated
Nov 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Oxaliplatin - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for First Line Metastatic Colorectal Small Bowel or Appendiceal Cancer
... Show more tags
Drugs Used:
PANitumumab,
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
Quick Link(s):
Regimen Monograph
Aug 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
... Show more tags
Drugs Used:
nivolumab,
ipilimumab
... Show more tags
Quick Link(s):
Regimen Monograph
Apr 2019